
Quarterly report 2023-Q3
added 12-12-2023
Akumin Net Debt 2011-2025 | AKU
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Akumin
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.21 B | 1.16 B | 493 M | 319 M | 98.2 M | 72.7 M | 26.7 M | 25.7 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.21 B | 25.7 M | 427 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Brainsway Ltd.
BWAY
|
-6.88 M | $ 17.13 | 1.66 % | $ 99.4 M | ||
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
DarioHealth Corp.
DRIO
|
-12.1 M | $ 12.15 | 2.14 % | $ 345 M | ||
|
DexCom
DXCM
|
-487 M | $ 66.06 | -1.34 % | $ 25.5 B | ||
|
Exact Sciences Corporation
EXAS
|
-560 M | $ 101.57 | 0.07 % | $ 18.8 B | ||
|
Burning Rock Biotech Limited
BNR
|
-76 M | $ 16.0 | 1.59 % | $ 172 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
-2.64 M | $ 1.56 | -3.7 % | $ 1.98 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 38.95 | 0.82 % | $ 1.08 B | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Danaher Corporation
DHR
|
13.6 B | $ 227.29 | 0.42 % | $ 166 B | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 26.94 | -0.74 % | $ 815 M | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Mettler-Toledo International
MTD
|
1.8 B | $ 1 408.65 | 1.08 % | $ 29.9 B | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
NeoGenomics
NEO
|
-23.3 M | $ 12.15 | 2.53 % | $ 1.54 B | ||
|
Neogen Corporation
NEOG
|
751 M | $ 6.84 | -0.36 % | $ 1.48 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
-48 M | $ 19.9 | -3.21 % | $ 1.07 B | ||
|
Pacific Biosciences of California
PACB
|
-139 M | $ 2.12 | - | $ 538 M | ||
|
Celcuity
CELC
|
82.8 M | $ 101.74 | -3.33 % | $ 4.01 B | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Anixa Biosciences
ANIX
|
-1.04 M | $ 3.35 | -6.42 % | $ 107 K | ||
|
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 26.46 | -0.62 % | $ 20 B | ||
|
Co-Diagnostics
CODX
|
-11.9 M | $ 0.3 | -13.39 % | $ 8.8 M | ||
|
Precipio
PRPO
|
-1.18 M | $ 24.67 | -1.2 % | $ 32 M | ||
|
Quidel Corporation
QDEL
|
-377 M | $ 28.82 | 0.07 % | $ 1.21 B | ||
|
IQVIA Holdings
IQV
|
11.2 B | $ 224.13 | 0.84 % | $ 40.6 B | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | $ 45.14 | -0.21 % | $ 10 B | ||
|
Guardant Health
GH
|
646 M | $ 103.55 | 1.45 % | $ 12.7 B | ||
|
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | ||
|
Sotera Health Company
SHC
|
1.94 B | $ 16.76 | -0.42 % | $ 4.74 B | ||
|
Soleno Therapeutics
SLNO
|
-20.8 M | $ 49.79 | -4.25 % | $ 2 B | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
Thermo Fisher Scientific
TMO
|
27.3 B | $ 574.27 | 0.46 % | $ 219 B | ||
|
Illumina
ILMN
|
-494 M | $ 134.66 | -0.16 % | $ 21.4 B | ||
|
Charles River Laboratories International
CRL
|
2.1 B | $ 197.59 | 2.36 % | $ 10.2 B | ||
|
Trinity Biotech plc
TRIB
|
55.4 M | $ 0.96 | -10.6 % | $ 61.9 M | ||
|
Twist Bioscience Corporation
TWST
|
-107 M | $ 31.39 | 1.47 % | $ 1.88 B | ||
|
Quotient Limited
QTNT
|
103 M | - | -11.32 % | $ 1.1 M | ||
|
Quest Diagnostics Incorporated
DGX
|
5.24 B | $ 184.04 | 0.81 % | $ 20.4 B | ||
|
Biodesix
BDSX
|
14.5 M | $ 7.63 | -2.8 % | $ 989 M | ||
|
Myriad Genetics
MYGN
|
115 M | $ 7.07 | -2.01 % | $ 641 M |